Emerin Is an Effector of Oncogenic KRAS-Driven Nuclear Dynamics in Pancreatic Cancer.

Using a model of PDAC, the major histological subtypes of pancreatic cancer, researchers found oncogenic mutant KRAS reduces nuclear size. Transcriptomic and protein expression analysis of mutant KRAS-expressing PDAC cells revealed differential levels of several nuclear envelope-associated genes.